Fig 1: GRK2 before (CHF) and after LVAD therapy (CHF+LVAD) as compared to non-failing ventricles (NF), left. The same analysis for the subgroups of patients with a duration of LVAD therapy above the median value, right (n = 10). GRK2 expression was determined by immunoblot (western blot) analysis and referred to a standard, respectively, whose densitometric value was set 1 by default. The value on the y-axis, therefore, reflects the percentage of each parameter's immunoblot band density in relation to this default value. AU arbitrary unit, CHF congestive heart failure, LVAD left ventricular assist device, NF non-failing myocardial tissue specimen